A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess safety, efficacy, and tolerability of pramlintide dose escalation with proactive mealtime insulin reduction, followed by insulin optimization, in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS—This 29-week, double-blind, placebo-controlled study randomized 296 patients to pramlintide or placebo as an adjunct to insulin. During initiation, pramlintide was escalated from 15 to 60 μg/meal (15-μg increments) with recommended reductions (30–50%) in mealtime insulin. Insulin was subsequently adjusted to optimize glycemic control. End points included safety and change in HbA1c (A1C), postprandial glucose, insulin, weight, and tolerability. RESULTS—Baseline A1C was 8.1% for both groups and at week 29 had decreased comparably (pramlintide −0.5% [95% CI −0.61 to −0.33]; placebo −0.5% [−0.63 to −0.35]). Pramlintide treatment significantly reduced postprandial glucose excursions (incremental area under the curve [AUC]0–3h: pramlintide −175 ± 40, placebo −64 ± 38 mg · h−1 · dl−1; P < 0.0005) and weight (pramlintide −1.3 ± 0.30, placebo +1.2 ± 0.30 kg; P < 0.0001). At week 29, insulin dose decreased by 28 and 4% in pramlintide- and placebo-treated groups, respectively. Nausea, reported by 63 and 36% of patients in pramlintide and placebo groups (P < 0.01), respectively, was predominately mild to moderate in intensity. Severe hypoglycemia rates were low in both groups (pramlintide 0.57 ± 0.09, placebo 0.30 ± 0.06 event rate/patient-year; P < 0.05), with increased rates observed in patients remaining at 30 μg pramlintide. CONCLUSIONS—Pramlintide dose escalation with reduced mealtime insulin was effective during therapy initiation in patients with type 1 diabetes. While both groups experienced equivalent A1C reductions relative to placebo, pramlintide-treated patients experienced reductions in postprandial glucose excursions and weight, not achievable with insulin therapy alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ultrarapid insulins (ie, faster aspart, lispro aabc) have demonstrated earlier time of onset and action but similar duration of action.1165”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1165]
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Ceriello, A., & Motz, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000122852.22604.78 · Cited by 1,378
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613
Balkau, B., Shipley, M., Jarrett, R. J., Pyörälä, K., Pyörälä, M., Forhan, A., & Eschwège, E. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 598
Purnell, J. Q., Hokanson, J. E., Marcovina, S. M., Steffes, M. W., Cleary, P. A., & Brunzell, J. D. (1998) · JAMA · doi:10.1001/jama.280.2.140 · Cited by 469
Should minimal blood glucose variability become the gold standard of glycemic control?
Hirsch, I. B., & Brownlee, M. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.10.001 · Cited by 405
Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial
The DCCT Research Group (1988) · Diabetes Care · doi:10.2337/diacare.11.7.567 · Cited by 345
Bryden, K. S., Neil, A., Mayou, R. A., Peveler, R. C., Fairburn, C. G., & Dunger, D. B. (1999) · Diabetes Care · doi:10.2337/diacare.22.12.1956 · Cited by 323
Donahue, R. P., Abbott, R. D., Reed, D. M., & Yano, K. (1987) · Diabetes · doi:10.2337/diab.36.6.689 · Cited by 316
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Self-citationWhitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Self-citationLowe, L. P., Liu, K., Greenland, P., Metzger, B. E., Dyer, A. R., & Stamler, J. (1997) · Diabetes Care · doi:10.2337/diacare.20.2.163 · Cited by 235
Lutz, T., Mollet, A., Rushing, P., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Self-citationGroup, T. D. C. A. C. T. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1711 · Cited by 205
Young, A. A., Gedulin, B., Vine, W., Percy, A., & Rink, T. J. (1995) · Diabetologia · doi:10.1007/bf00401833 · Cited by 184
Dose-response for glucagonostatic effect of amylin in rats
Gedulin, B. R., Rink, T. J., & Young, A. A. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90170-0 · Cited by 180
Power of the two one-sided tests procedure in bioequivalence
Phillips, K. F. (1990) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01063556 · Cited by 145
Progression of Coronary Artery Calcification in Type 1 Diabetes
Snell-Bergeon, J. K., Hokanson, J. E., Jensen, L., MacKenzie, T., Kinney, G., Dabelea, D., Eckel, R. H., Ehrlich, J., Garg, S., & Rewers, M. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2923 · Cited by 139
Self-citationWeyer, C., Gottlieb, A., Kim, D. D., Lutz, K., Schwartz, S., Gutierrez, M., Wang, Y., Ruggles, J. A., Kolterman, O. G., & Maggs, D. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3074 · Cited by 107
Self-citationDonahue, R. P., Abbott, R. D., Reed, D. M., et al. (1987) · Diabetes · doi:10.2337/diabetes.36.6.689 · Cited by 90
Amylinʼs physiology and its role in diabetes
Young, A. A. (1997) · Current Opinion in Endocrinology and Diabetes · doi:10.1097/00060793-199708000-00006 · Cited by 87
Home, P. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x49662 · Cited by 82
Amylin and Insulin Interact to Reduce Food Intake in Rats
Rushing, P., Lutz, T., Seeley, R., & Woods, S. (2000) · Hormone and Metabolic Research · doi:10.1055/s-2007-978590 · Cited by 62
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Metadata
- Authors
- Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O.
- Affiliations
- Division of Diabetes/Metabolism, San Diego VA Medical Center, San Diego, California
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-10-01
- Volume
- 29
- Issue
- 10
- Pages
- 2189-2195
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126969411
- Cited by
- 166
- References
- 25
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 15 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, intensive insulin therapy, glycemic control, HbA1c, postprandial blood glucose, weight loss, nausea, hypoglycemia, GLP-1 receptor agonists, dose escalation, weight gain, weight loss maintenance
- MeSH terms
- Adult, Amyloid, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Eating, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.